|By PR Newswire||
|September 4, 2014 07:00 AM EDT|
SANTA ROSA, Calif., Sept. 4, 2014 /PRNewswire/ -- Ruthigen, Inc., (NASDAQ: RTGN) a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics designed to prevent and treat infection in invasive applications, today announced that the Company is scheduled to present at the Rodman & Renshaw 16th Annual Global Investment Conference on Wednesday, September 10, 2014 at 2:30 p.m. ET. The conference will be held at the New York Palace Hotel in New York City.
A live webcast of Ruthigen's presentation may be available at the following website: http://wsw.com/webcast/rrshq24/rtgn. After the presentation, a replay will be archived and accessible for 90 days at the same website.
Ruthigen is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics designed to prevent and treat infection in invasive applications. The Company's lead drug candidate, RUT58-60, is a broad-spectrum anti-infective containing a new formulation of hypochlorous acid, HOCl, with small molecule stabilizers that Ruthigen is developing for the prevention and treatment of infection in surgical and trauma procedures. RUT58-60 uses a mechanism of action designed to prevent emergence of bacterial resistance and improves patient safety by neither targeting specific bacterial cell membrane receptors nor exposing patient's vital organs to unnecessary systemic drugs. The Company plans to complete its Phase I/II clinical trial in Q1 2015 and pending the successful completion of that trial, Ruthigen plans to conduct pivotal clinical trials. The Company's clinical program targets an initial $700M potential market in the prevention of infections associated with abdominal surgery. The Company believes the market for prevention of infection in the U.S. surgical market is estimated at $3B. For more information, visit www.ruthigen.com.
SOURCE Ruthigen, Inc.
DevOps is being widely accepted (if not fully adopted) as essential in enterprise IT. But as Enterprise DevOps gains maturity, expands scope, and increases velocity, the need for data-driven decisions across teams becomes more acute. DevOps teams in any modern business must wrangle the ‘digital exhaust’ from the delivery toolchain, "pervasive" and "cognitive" computing, APIs and services, mobile devices and applications, the Internet of Things, and now even blockchain. In this power panel at @...
Oct. 22, 2016 07:45 PM EDT Reads: 1,813
Oct. 22, 2016 07:00 PM EDT Reads: 761
Oct. 22, 2016 06:45 PM EDT Reads: 612
Oct. 22, 2016 06:00 PM EDT Reads: 8,956
Oct. 22, 2016 05:30 PM EDT Reads: 480
Oct. 22, 2016 05:30 PM EDT Reads: 969
Oct. 22, 2016 04:00 PM EDT Reads: 3,843
Oct. 22, 2016 04:00 PM EDT Reads: 3,657
Oct. 22, 2016 04:00 PM EDT Reads: 3,583
Oct. 22, 2016 03:45 PM EDT Reads: 1,442
Oct. 22, 2016 03:45 PM EDT Reads: 652
Oct. 22, 2016 03:30 PM EDT Reads: 2,245
Oct. 22, 2016 03:00 PM EDT Reads: 3,894
Oct. 22, 2016 02:45 PM EDT Reads: 1,502
Oct. 22, 2016 02:45 PM EDT Reads: 1,541